Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.586 EUR | -0.68% | -3.93% | -45.74% |
May. 15 | BenevolentAI Announces Further Success with AstraZeneca Collaboration as Novel Heart Failure Target Selected | CI |
May. 02 | Benevolentai S.A. Announces Directorate Changes | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company appears to be poorly valued given its net asset value.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-45.74% | 78.25M | - | ||
+48.67% | 58.71B | B- | ||
-2.76% | 41.31B | B | ||
+36.42% | 39.2B | A | ||
-11.22% | 27.4B | C | ||
+9.25% | 26.55B | B- | ||
-23.10% | 18.98B | B | ||
+1.88% | 12.51B | B+ | ||
+26.43% | 12.08B | C+ | ||
+21.74% | 11.94B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BAI Stock
- Ratings BenevolentAI